These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 16330610

  • 1. Parkinsonism with intramuscular ziprasidone.
    Bilal L, Tsai C, Gasper JJ, Ndlela JC.
    Am J Psychiatry; 2005 Dec; 162(12):2392-3. PubMed ID: 16330610
    [No Abstract] [Full Text] [Related]

  • 2. Ziprasidone-induced acute dystonia.
    Mason MN, Johnson CE, Piasecki M.
    Am J Psychiatry; 2005 Mar; 162(3):625-6. PubMed ID: 15741487
    [No Abstract] [Full Text] [Related]

  • 3. Third degree heart block following intramuscular ziprasidone.
    Tambyraja R, Strawn JR.
    Schizophr Res; 2011 Feb; 125(2-3):302-3. PubMed ID: 20692812
    [No Abstract] [Full Text] [Related]

  • 4. Parenteral ziprasidone: a new atypical neuroleptic for emergency treatment of psychosis in Parkinson's disease?
    Oechsner M, Korchounov A.
    Hum Psychopharmacol; 2005 Apr; 20(3):203-5. PubMed ID: 15799011
    [Abstract] [Full Text] [Related]

  • 5. [Ziprasidone-augmentation of clozapine].
    Zink M, Mase E, Dressing H.
    Psychiatr Prax; 2004 Jul; 31(5):259-61. PubMed ID: 15243877
    [Abstract] [Full Text] [Related]

  • 6. Clozapine and ziprasidone: a useful combination in patients with treatment-resistant schizophrenia.
    Ziegenbein M, Calliess IT.
    J Neuropsychiatry Clin Neurosci; 2006 Jul; 18(2):246-7. PubMed ID: 16720806
    [No Abstract] [Full Text] [Related]

  • 7. A case of catatonia successfully treated with ziprasidone, in a patient with DSM-IV delusional disorder.
    Angelopoulos EK, Corcondilas M, Kollias CT, Kioulos KT, Bergiannaki JD, Papadimitriou GN.
    J Clin Psychopharmacol; 2010 Dec; 30(6):745-6. PubMed ID: 21057243
    [No Abstract] [Full Text] [Related]

  • 8. Rhabdomyolysis after correction of hyponatremia in psychogenic polydipsia possibly complicated by ziprasidone.
    Zaidi AN.
    Ann Pharmacother; 2005 Oct; 39(10):1726-31. PubMed ID: 16131536
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Strategies for successful clinical management of schizophrenia with ziprasidone.
    Fagiolini A, Cañas F, Gallhofer B, Larmo I, Levy P, Montes JM, Papageorgiou G, Zink M, Rossi A.
    Expert Opin Pharmacother; 2010 Sep; 11(13):2199-220. PubMed ID: 20658947
    [Abstract] [Full Text] [Related]

  • 16. [Risk of QTc prolongation due to combination of ziprasidone and quetiapine].
    Minov C.
    Psychiatr Prax; 2004 Nov; 31 Suppl 1():S142-4. PubMed ID: 15570533
    [Abstract] [Full Text] [Related]

  • 17. Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly patients: retrospective findings from a psychiatric emergency service.
    Kohen I, Preval H, Southard R, Francis A.
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):240-5. PubMed ID: 16503319
    [Abstract] [Full Text] [Related]

  • 18. Chronic Pisa syndrome associated with switching antipsychotics from olanzapine to ziprasidone.
    Yeh YW, Chen YC, Chen CK, Feng HM, Wang TY, Chen CL.
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Feb 01; 33(1):162-3. PubMed ID: 19028541
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.